Intratect

Human normal immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as a solution for injection for intravenous use. It replaces missing antibodies and modulates immune activity in primary and secondary immunodeficiency diseases and selected immune‑mediated disorders.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Clients benefit from reliable cold‑chain logistics and responsive technical support throughout the supply chain.

Intratect, an intravenous immunoglobulin, is used to replace deficient antibodies and modulate immune responses in several immunologic conditions. - Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. - Secondary immunodeficiency (e.g., chemotherapy‑induced): provides passive immunity during immune suppression. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces inflammation and coronary artery complications in acute phase. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability. - Multifocal motor neuropathy: enhances motor function by neutralizing pathogenic antibodies.

Intratect may be associated with a range of infusion‑related and systemic reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient rise in temperature and shaking sensations. - Nausea or vomiting: gastrointestinal discomfort following administration. - Fatigue: temporary tiredness reported by many patients.

Serious or Rare Side Effects: - Aseptic meningitis: severe headache with neck stiffness, requiring medical evaluation. - Thromboembolic events: blood clots that can affect veins or arteries. - Acute renal failure: sudden loss of kidney function, especially with high infusion rates. - Anaphylaxis or severe allergic reaction: rapid onset of breathing difficulty, rash, or hypotension.

Before using Intratect, healthcare providers should observe several safety measures. - Screen for IgA deficiency: test patients for anti‑IgA antibodies to avoid severe reactions. - Monitor renal function: assess serum creatinine and urine output before and during therapy. - Assess thrombotic risk: evaluate history of clotting disorders and consider prophylactic measures. - Avoid in patients with known severe allergic reactions to immunoglobulins: discontinue if hypersensitivity occurs. - Discuss use in pregnancy and lactation: weigh potential benefits against unknown risks with the prescriber. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent use may diminish vaccine effectiveness; schedule separately. - High‑dose cytotoxic chemotherapy: combined nephrotoxic potential increases risk of renal injury. - Anticoagulants (e.g., warfarin) at high doses: may enhance bleeding tendency due to platelet interaction.

Moderate Interactions (Monitor Closely): - Diuretics: monitor fluid balance and renal parameters during infusion. - ACE inhibitors: watch for additive hypotensive effects. - Rituximab: may alter response to immunoglobulin therapy; assess clinical outcome.